Literature DB >> 18054517

Dendritic cells and cytokines in immune rejection of cancer.

Maria Ferrantini1, Imerio Capone, Filippo Belardelli.   

Abstract

Dendritic cells (DCs) play a crucial role in linking innate and adaptive immunity and, thus, in the generation of a protective immune response against both infectious diseases and tumors. The ability of DCs to prime and expand an immune response is regulated by signals acting through soluble mediators, mainly cytokines and chemokines. Understanding how cytokines influence DC functions and orchestrate the interactions of DCs with other immune cells is strictly instrumental to the progress in cancer immunotherapy. Herein, we will illustrate how certain cytokines and immune stimulating molecules can induce and sustain the antitumor immune response by acting on DCs. We will also discuss these cytokine-DC interactions in the light of clinical results in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18054517     DOI: 10.1016/j.cytogfr.2007.10.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  20 in total

1.  DC maturation and function are not altered by melanoma-derived immunosuppressive soluble factors.

Authors:  Joel M Baumgartner; Kimberly R Jordan; Ling-Jia Hu; Cara C Wilson; Anirban Banerjee; Martin D McCarter
Journal:  J Surg Res       Date:  2011-08-24       Impact factor: 2.192

2.  Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape.

Authors:  Li Wenbo; Jin Wang
Journal:  J R Soc Interface       Date:  2017-06       Impact factor: 4.118

Review 3.  Tumor cell lysates as immunogenic sources for cancer vaccine design.

Authors:  Fermín E González; Alejandra Gleisner; Felipe Falcón-Beas; Fabiola Osorio; Mercedes N López; Flavio Salazar-Onfray
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-γ-induced Indoleamine 2,3-Dioxygenase Expression.

Authors:  Kyung Tae Noh; Kwang Hee Son; In Duk Jung; Tae Heung Kang; Chang Hun Choi; Yeong-Min Park
Journal:  J Biol Chem       Date:  2015-03-26       Impact factor: 5.157

5.  Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.

Authors:  Sarmishtha De; Hao Zhou; David DeSantis; Colleen M Croniger; Xiaoxia Li; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-20       Impact factor: 11.205

6.  Enhancement of anti-Aspergillus T helper type 1 response by interferon-β-conditioned dendritic cells.

Authors:  Valérie Gafa; Maria E Remoli; Elena Giacomini; Martina Severa; Renée Grillot; Eliana M Coccia
Journal:  Immunology       Date:  2010-10       Impact factor: 7.397

7.  Monocyte-derived dendritic cells from patients with cervical intraepithelial lesions.

Authors:  Angela Maria Moed Lopes; Márcia Antoniazi Michelin; Eddie Fernando Cândido Murta
Journal:  Oncol Lett       Date:  2017-01-11       Impact factor: 2.967

Review 8.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02

9.  Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.

Authors:  Petra Cerkovnik; Barbara Jezersek Novakovic; Vida Stegel; Srdjan Novakovic
Journal:  BMC Immunol       Date:  2010-09-13       Impact factor: 3.615

10.  Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.

Authors:  Amorette Barber; Charles L Sentman
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.